Akash Bhanshali Portfolio Stock Gains Rs 872,507,400 In A Single Day As Pharma Company Jumps Over 7%; FII Holding Rises to 28%
Om DSIJ / 27 Jul 2026 / Categories: Mindshare, Trending
Laurus Labs witnessed increased foreign institutional participation during the June 2026 quarter, while ace investor Akash Bhanshali retained his stake as the stock surged over 7 per cent.
On Monday, Indian equity benchmark indices traded higher, with the benchmark Nifty 50 index rising 235.75 points, or 0.99 per cent, to 24,003.20. Amid the positive market sentiment, Laurus Labs share price jumped 7.73 per cent to Rs 1,725.00, gaining 123.80 points during the trading session.
Laurus Labs FII Holding Increases
The company's latest shareholding pattern for the quarter ended June 2026 showed that Foreign Institutional Investors (FIIs) increased their stake to 28.00 per cent from 25.82 per cent in March 2026. Meanwhile, Domestic Institutional Investors (DIIs) marginally reduced their holding to 13.73 per cent from 13.96 per cent during the same period.
Promoter holding remained largely stable at 27.47 per cent, compared with 27.49 per cent in the previous quarter.
Also Read - Stock Below Rs 30: Small-Cap Steel Company Achieves Key Milestone With 1 MW Captive Solar Project; Power Generation Expected in August
Akash Bhanshali Continues to Hold 1.32 Per cent Stake
Ace Investor Akash Bhanshali continued to hold a 1.32 per cent stake in Laurus Labs as of June 2026, unchanged from the previous quarter.
Based on his holding of 7,151,700 equity shares, Monday's gain of 123.80 points increased the market value of his investment by approximately Rs 88,53,80,460 in a single trading session.
Laurus Labs Share Price Performance
Laurus Labs has delivered strong returns across multiple time periods. The stock has gained 14.94 per cent over the past one month, 72.41 per cent in the last six months, and 93.92 per cent over the past one year, reflecting sustained investor interest.
Searching for the Next Multibagger Opportunity?
Explore DSIJ’s Multibagger Pick - a research-driven service focused on identifying fundamentally strong companies with the potential to generate exceptional long-term returns.
Download Service BrochureAbout Laurus Labs
Laurus Labs Ltd is a leading pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs), contract development and manufacturing (CDMO) services, and specialty ingredients. The company serves customers across more than 80 countries with a diversified portfolio spanning antiretrovirals, oncology, cardiovascular, diabetes and other therapeutic segments.
The company has a strong global manufacturing footprint with multiple regulatory-approved facilities and continues to invest in research, innovation and capacity expansion. Laurus Labs has strengthened its position as a key partner for global pharmaceutical companies through its integrated manufacturing capabilities and growing CDMO business.
Add DSIJ as your preferred news source on G o o g l e
Add NowShare your thoughts on Laurus Labs' latest shareholding changes in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.